EBMT Risk Score

EBMT Risk Score: The Gratwohl score for allogeneic HSCT. Predicts survival and transplant-related mortality using universal pre-transplant factors.

Age at Transplant

Disease Stage

Donor Type

Time: Diagnosis to Tx

Donor/Recipient Sex

Total EBMT Risk Score

0

Estimated Survival Probability

High (~70%)

Guidelines & Evidence

Verified

Last Review: 2026-07-17

When to Use

Initial risk stratification for patients undergoing allogeneic Hematopoietic Stem Cell Transplantation (HSCT).

Predicting Transplant-Related Mortality (TRM) and Overall Survival (OS) pre-transplant.

Counselling patients regarding the relative risks of different transplant strategies (e.g., sibling vs. unrelated donor).

Patient Population

Derived and validated in adult patients with hematologic malignancies (CML, AML, ALL, MDS, Myeloma, Lymphoma) across EBMT-affiliated centers.

When Not to Rely on This Score Alone

Non-malignant conditions (e.g., Sickle Cell Disease) — the score weighting is malignant-specific.

Reduced Intensity Conditioning (RIC) — the score was primarily developed in the mieloablative era, though it remains broadly discriminative.

Pediatric patients — age-related risks and donor outcomes differ in children.

How it Works

Scoring Components

Factor	Score 0	Score 1	Score 2
Age (yr)	< 20	20 - 40	> 40
Disease Stage	Early	Intermediate	Late
Time to Tx	< 12 months	> 12 months	-
Donor Type	HLA-Identical Sibling	Unrelated	-
Donor/Recip Sex	Other	Female Donor to Male Recipient	-

Defining Stages

Early: CR1 (AML, ALL, NHL), CP1 (CML), or Untreated (MDS).

Intermediate: CR2/CR3 or Intermediate Phases.

Late: Active disease at transplant, Relapsed/Refractory, or Blast Crisis.

Last Comprehensive Review: 2026-07-17

Recent Journal Updates

British J HaematologyJul 22, 2026

Immunoglobulin replacement after chimeric antigen receptor T‐cell therapy in large B‐cell lymphoma with hypogammaglobulinaemia: Secondary Center for International Blood and Marrow Transplant Research analysis

Clinical Context

We think this has broad domain relevance to EBMT Risk Score for HSCT.

British J HaematologyJul 22, 2026

Avatrombopag for persistent and chronic immune thrombocytopenia in children: A post hoc analysis of clinical characteristics of response from a phase 3b clinical trial

Clinical Context

We think this has broad domain relevance to EBMT Risk Score for HSCT.

British J HaematologyJul 17, 2026

Hyperglycaemia as a predictor of morbidity and mortality in patients receiving an allogeneic haematopoietic stem cell transplantation

Clinical Context

We think this has broad domain relevance to EBMT Risk Score for HSCT.

EBMT Risk Score

Age at Transplant

Disease Stage

Donor Type

Time: Diagnosis to Tx

Donor/Recipient Sex

0

High (~70%)

When to Use

When to Use

Patient Population

When Not to Rely on This Score Alone

How it Works

Scoring Components

Defining Stages

Clinical Pearls

The "Female to Male" Factor

The Evidence

Primary Score

Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the EBMT.

The EBMT risk score.

Origins & History

Development

Recent Journal Updates

EBMT Risk Score

Age at Transplant

Disease Stage

Donor Type

Time: Diagnosis to Tx

Donor/Recipient Sex

0

High (~70%)

When to Use

When to Use

Patient Population

When Not to Rely on This Score Alone

How it Works

Scoring Components

Defining Stages

Clinical Pearls

The "Female to Male" Factor

The Evidence

Primary Score

Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the EBMT.

The EBMT risk score.

Origins & History

Development

Recent Journal Updates